Natus Medical Inc (BABY) Shares Sold by Teachers Advisors LLC

Teachers Advisors LLC decreased its position in Natus Medical Inc (NASDAQ:BABY) by 3.4% in the fourth quarter, Holdings Channel reports. The fund owned 55,720 shares of the medical equipment provider’s stock after selling 1,940 shares during the period. Teachers Advisors LLC’s holdings in Natus Medical were worth $2,129,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in shares of Natus Medical during the 3rd quarter valued at about $138,000. Greenwood Capital Associates LLC purchased a new position in shares of Natus Medical during the 4th quarter valued at about $219,000. First Capital Advisors Group LLC. purchased a new position in shares of Natus Medical during the 4th quarter valued at about $222,000. Bessemer Group Inc. purchased a new position in shares of Natus Medical during the 4th quarter valued at about $255,000. Finally, Stone Ridge Asset Management LLC purchased a new position in shares of Natus Medical during the 4th quarter valued at about $303,000. Institutional investors own 95.83% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of Natus Medical stock opened at $35.05 on Tuesday. The company has a quick ratio of 2.54, a current ratio of 3.32 and a debt-to-equity ratio of 0.37. Natus Medical Inc has a twelve month low of $28.00 and a twelve month high of $43.60. The stock has a market capitalization of $1,162.27, a P/E ratio of 24.01 and a beta of 0.47.

Natus Medical (NASDAQ:BABY) last announced its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.54 by ($0.12). Natus Medical had a negative net margin of 4.05% and a positive return on equity of 11.36%. The business had revenue of $131.40 million during the quarter, compared to analysts’ expectations of $131.38 million. During the same quarter in the prior year, the firm earned $0.51 EPS. Natus Medical’s revenue for the quarter was up 22.0% on a year-over-year basis. analysts forecast that Natus Medical Inc will post 1.63 earnings per share for the current fiscal year.

Natus Medical declared that its Board of Directors has authorized a stock buyback plan on Thursday, February 22nd that allows the company to repurchase $30.00 million in shares. This repurchase authorization allows the medical equipment provider to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

In related news, Director Ken Ludlum sold 4,000 shares of Natus Medical stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $31.68, for a total value of $126,720.00. Following the completion of the transaction, the director now owns 93,825 shares in the company, valued at approximately $2,972,376. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 5.50% of the stock is owned by insiders.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Natus Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 10th. BidaskClub upgraded Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 17th. Roth Capital set a $39.00 price objective on Natus Medical and gave the company a “buy” rating in a research note on Tuesday, February 27th. Benchmark reiterated a “buy” rating and set a $49.00 price objective (down previously from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. Finally, William Blair lowered Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $44.33.

ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.

Leave a Reply